The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month, the company's shares ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.

In 1956, Lever differentiated BP from the other bullous diseases based on the specific immunohistological characteristics of BP (Bolognia et al., 2008) and, in 1967, Jordon and colleagues ...

Bullous pemphigoid (BP), usually seen in the elderly, is the most common autoimmune blistering disease. The various clinical presentations of BP, similar and associated diseases, and the ...

Porphyria cutanea tarda (PCT) is a metabolic disease of the heme synthesizing enzyme, uroporphyrinogen decarboxylase, which leads to a buildup of toxic heine precursors. Manifestations of porphyria ...

Sanofi and Regeneron's Dupixent is effective in two skin disorders, bullous pemphigoid and chronic spontaneous urticaria. Skip to main content Wednesday 25 June 2025 . BlueSky ...